{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:42:34Z","timestamp":1786372954342,"version":"build-2736575974"},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.2215\/cjn.04820610","type":"journal-article","created":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T20:56:28Z","timestamp":1289508988000},"page":"2355-2362","source":"Crossref","is-referenced-by-count":16,"title":["Bundled-Rate Legislation for Medicare Reimbursement for Dialysis Services"],"prefix":"10.2215","volume":"5","author":[{"given":"Chaim","family":"Charytan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-30-20230601","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1053\/j.ajkd.2008.09.001","article-title":"Economic considerations in a changing anemia environment","volume":"52","author":"Pizzi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R4-30-20230601","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1038\/sj.ki.5001972","article-title":"The economic realities of erythropoiesis-stimulating agent therapy in kidney disease","volume":"70","author":"Wish","year":"2006","journal-title":"Kidney Int"},{"key":"R5-30-20230601","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/jama.297.15.1667","article-title":"Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis","volume":"297","author":"Thamer","year":"2007","journal-title":"JAMA"},{"key":"R10-30-20230601","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"R11-30-20230601","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"R12-30-20230601","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"R13-30-20230601","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1056\/NEJM199808273390902","article-title":"Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis","volume":"339","author":"Kaufman","year":"1998","journal-title":"N Engl J Med"},{"key":"R14-30-20230601","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/01.ASN.0000107561.59698.42","article-title":"Anti-erythropoietin antibodies and pure red cell aplasia","volume":"15","author":"Rossert","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R15-30-20230601","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000111115","article-title":"C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks","volume":"28","author":"Spinowitz","year":"2008","journal-title":"Am J Nephrol"},{"key":"R16-30-20230601","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1093\/ndt\/gfn416","article-title":"A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: A German prospective, randomized, multicentre study","volume":"23","author":"Bommer","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R18-30-20230601","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1053\/j.ajkd.2008.09.003","article-title":"A comprehensive vision for intravenous iron therapy","volume":"52","author":"Coyne","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R19-30-20230601","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1053\/j.ajkd.2008.09.004","article-title":"Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron","volume":"52","author":"Kapoian","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R20-30-20230601","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1681\/ASN.2007050606","article-title":"Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin","volume":"19","author":"Kapoian","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R21-30-20230601","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1681\/ASN.V113530","article-title":"Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients","volume":"11","author":"Besarab","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R22-30-20230601","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2006091034","article-title":"Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study","volume":"18","author":"Coyne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R23-30-20230601","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1755-6686.2009.00125.x","article-title":"Iron therapy in chronic kidney disease: Current controversies","volume":"35","author":"Kovesdy","year":"2009","journal-title":"J Renal Care"},{"key":"R24-30-20230601","first-page":"7","article-title":"Pathophysiology of iron overload","volume":"19","author":"Porter","year":"2005","journal-title":"Hematol Oncol Clin North Am"},{"key":"R25-30-20230601","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/ajh.21682","article-title":"Anemia management in chronic kidney disease: Intravenous iron steps forward","volume":"85","author":"Coyne","year":"2010","journal-title":"Am J Hematol"},{"key":"R26-30-20230601","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ajh.21656","article-title":"FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease","volume":"85","author":"Lu","year":"2010","journal-title":"Am J Hematol"},{"key":"R27-30-20230601","first-page":"662A","article-title":"Initial dose conversion ratio of epoetin alfa to darbepoetin alfa does not predict future need for darbepoetin alfa in HD patients [SA-PO2407]","volume":"20","author":"Besarab","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R28-30-20230601","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1440-1797.2007.00810.x","article-title":"Erythropoiesis-stimulating agent hyporesponsiveness","volume":"12","author":"Johnson","year":"2007","journal-title":"Nephrology"},{"key":"R29-30-20230601","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/blood-2008-07-077370","article-title":"The hazards of blood transfusion in historical perspective","volume":"112","author":"Alter","year":"2008","journal-title":"Blood"},{"key":"R30-30-20230601","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/ndt\/13.8.2027","article-title":"Sensitization to human leukocyte antigen before and after the introduction of erythropoietin","volume":"13","author":"Vella","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"R31-30-20230601","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1053\/j.ajkd.2008.12.040","article-title":"Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients","volume":"53","author":"Kalantar-Zadeh","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R32-30-20230601","first-page":"46A","article-title":"Dialysis facility-level racial variation and EPO costs: geographic representations [F-FC195]","volume":"20","author":"Dunning","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R34-30-20230601","first-page":"47A","article-title":"Accounting for race and ethnicity in a dialysis prospective payment system [F-FC197]","volume":"20","author":"Roach","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R35-30-20230601","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1053\/ajkd.2002.34924","article-title":"Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access","volume":"40","author":"Lee","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R38-30-20230601","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1742-1241.2008.01846.x","article-title":"Extended administration of erythropoiesis-stimulating agents for optimising the management of renal anaemia: What is the evidence?","volume":"62","author":"Roger","year":"2008","journal-title":"Int J Clin Pract"},{"key":"R40-30-20230601","doi-asserted-by":"crossref","first-page":"697","DOI":"10.5414\/CNP71697","article-title":"Parameters for successful monthly extended dosing of darbepoetin-alpha in patients undergoing hemodialysis","volume":"71","author":"Trachsler","year":"2009","journal-title":"Clin Nephrol"},{"key":"R41-30-20230601","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/ndt\/gfh021","article-title":"Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients","volume":"19","author":"Jadoul","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R42-30-20230601","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.ajkd.2007.08.013","article-title":"Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: A randomized trial","volume":"50","author":"Klinger","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"R43-30-20230601","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2215\/CJN.03631006","article-title":"Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly","volume":"2","author":"Sulowicz","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R44-30-20230601","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(07)61599-2","article-title":"Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: A randomised non-inferiority trial (MAXIMA)","volume":"370","author":"Levin","year":"2007","journal-title":"Lancet"},{"key":"R45-30-20230601","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1093\/ndt\/gfn320","article-title":"Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: Results from STRIATA, a randomized phase III study","volume":"23","author":"Canaud","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R49-30-20230601","first-page":"364A","article-title":"Interim analysis of once-monthly Hematide efficacy and safety in HD patients not on ESA treatment [F-PO1094]","volume":"20","author":"Gurevich","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"R50-30-20230601","doi-asserted-by":"crossref","first-page":"B1","DOI":"10.1053\/j.ajkd.2008.02.090","article-title":"Interim evaluation of long-term safety and tolerability of Hematide\u2122 during maintenance treatment of anemia in patients with CKD on hemodialysis [Abstract # 550961]","volume":"51","author":"Geronemus","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R52-30-20230601","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.exphem.2007.05.007","article-title":"Hematide\u2122 is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model","volume":"35","author":"Woodburn","year":"2007","journal-title":"Exp Hematol"},{"key":"R53-30-20230601","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1056\/NEJMoa074037","article-title":"A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia","volume":"361","author":"Macdougall","year":"2009","journal-title":"N Engl J Med"},{"key":"R54-30-20230601","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1542-4758.2008.00308.x","article-title":"Costs of managing anemia with erythropoieses-stimulating agents during hemodialysis: A time and motion study","volume":"12","author":"Schiller","year":"2008","journal-title":"Hemodial Int"},{"key":"R55-30-20230601","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1159\/000171873","article-title":"Healthcare resource utilization for anemia management: Current practice with erythropoiesis-stimulating agents and the impact of converting to once-monthly C.E.R.A","volume":"26","author":"Saueressig","year":"2008","journal-title":"Blood Purif"},{"key":"R56-30-20230601","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/jama.281.13.1211","article-title":"An international study of patient compliance with hemodialysis","volume":"281","author":"Bleyer","year":"1999","journal-title":"JAMA"},{"key":"R57-30-20230601","first-page":"146","article-title":"Anemia severity and missed dialysis treatments in erythropoietin-treated hemodialysis patients","volume":"42","author":"Ifudu","year":"1996","journal-title":"ASAIO J"},{"key":"R58-30-20230601","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/ajkd.1998.v32.pm9669435","article-title":"Noncompliance in hemodialysis: Predictors and survival analysis","volume":"32","author":"Leggat","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R59-30-20230601","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1046\/j.1523-1755.2003.00064.x","article-title":"Nonadherence in hemodialysis: Associations with mortality, hospitalization, and practice patterns in the DOPPS","volume":"64","author":"Saran","year":"2003","journal-title":"Kidney Int"},{"key":"R60-30-20230601","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/ajkd.2002.34925","article-title":"Factors influencing erythropoietin compliance in peritoneal dialysis patients","volume":"40","author":"Wazny","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R61-30-20230601","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1345\/aph.1M429","article-title":"Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy","volume":"44","author":"Brophy","year":"2010","journal-title":"Ann Pharmacother"},{"key":"R62-30-20230601","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1542-4758.2008.00278.x","article-title":"Factors affecting anemia management in hemodialysis patients: A single-center experience","volume":"12","author":"Spiegel","year":"2008","journal-title":"Hemodial Int"},{"key":"R63-30-20230601","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000046281","article-title":"Erythropoietin requirements increase following hospitalization in end-stage renal disease patients","volume":"21","author":"Yaqub","year":"2001","journal-title":"Am J Nephrol"},{"key":"R64-30-20230601","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1542-4758.2007.00215.x","article-title":"Perihospitalization hemoglobin-epoetin associations in U.S. hemodialysis patients, 1998 to 2003","volume":"11","author":"Solid","year":"2007","journal-title":"Hemodial Int"},{"key":"R65-30-20230601","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/ki.2010.108","article-title":"International trends in erythropoietin use and hemoglobin levels in hemodialysis patients","volume":"78","author":"McFarlane","year":"2010","journal-title":"Kidney Int"},{"key":"R66-30-20230601","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1093\/ndt\/gfq336","article-title":"Target haemoglobin to aim for with erythropoiesis-stimulating agents: A position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp\u00ae Therapy (TREAT) Study","volume":"25","author":"Locatelli","year":"2010","journal-title":"Nephrol Dial Transplant"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201012000-00030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:40:30Z","timestamp":1786369230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201012000-00030"}},"subtitle":["Implications for Anemia Management with ESAs"],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.04820610","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}